EuropeSouth AsiaAsia PacificAmericasMiddle EastAfricaBBC HomepageWorld ServiceEducation
News image
News image
News image
News imageNews image
News image
Front Page
News image
World
News image
UK
News image
UK Politics
News image
Business
News image
Sci/Tech
News image
Health
News image
Education
News image
Sport
News image
Entertainment
News image
Talking Point
News image
In Depth
News image
On Air
News image
Archive
News image
News image
News image
Feedback
Low Graphics
Help
News imageNews imageNews image
News imageWednesday, November 10, 1999 Published at 01:25 GMT
News image
News image
Health
News image
Scientists quarrel over gene therapy
News image
UK scientists take strict safety precautions over gene therapy treatments
News image
A US drug company has admitted gene therapies under trial on liver cancer patients have caused serious side effects - but British experts say the technology is safe.

The American regulatory authorities are focusing on new treatments which use a de-activated cold virus, or adenovirus, to carry genes into the human body.

In September, an 18-year-old Arizona man, Jesse Gelsinger, died of liver problems following such treatment.

Last week drug manufacturer Schering-Plough said three others had suffered unspecified serious side effects.

There are also concerns surrounding the deaths of six people taking part in an trial of a gene therapy designed to help patients grow new blood vessels around blocked ones, although the doctors involve say they died of underlying illnesses.

But scientists carrying out gene therapy experiments in this country have stressed the safety of the viruses.


[ image: Some animals have been harmed by very high doses of adenovirus]
Some animals have been harmed by very high doses of adenovirus
Professor Stan Kaye, from the department of medical oncology at the Western Infirmary in Glasgow, is involved in a study in which viruses are injected into head and neck tumours.

He said: "I'm totaly confident of the safety of the virus.

"There is a genetic alteration which makes it harmless."

Professor David Kerr,a consultant in clinical oncology at the University of Birmingham, says the trial which ended in the death of Mr Gelsinger used huge doses of virus, whereas most other studies used them in comparatively tiny numbers.

Neutered virus

The starting dose his team are using contains approximately 10 million times fewer viruses.

He said: "The viruses have been neutered - we snip out the part of their genetic code which allows them to replicate."

Some scientists fear if a modified virus met a natural, or "wild" virus, a novel virus might be the result.

But despite the efforts of many, this had never been found to happen, even in the laboratory.

He said: "We are working with patients who have terminal cancer, perhaps only three to six months left.

"We are starting with very small doses and increasing them cautiously and carefully.

"We have done a lot of work with animal models, and although some rodents are susceptible to liver damage, the doses you have to give to achieve this are massive," said Mr Gelsinger.



News image


Advanced options | Search tips


News image
News image
News imageBack to top | BBC News Home | BBC Homepage |
News image

News imageNews imageNews image
Health Contents
News image
News imageBackground Briefings
News imageMedical notes
News imageNews image
Relevant Stories
News image
25 Oct 99�|�Health
Mouse gene therapy 'boosts poor diet'
News image
07 Oct 99�|�Health
Genetically-modified veins could save lives
News image
14 Sep 99�|�Health
Gene therapy threat to cancer nurses
News image
04 Jul 99�|�Health
Gene therapy doctor suspended
News image
18 May 99�|�Health
'New era for cancer treatment'
News image

News image
News image
News image
News imageInternet Links
News image
News imageNews image
Cancer Research Campaign
News image
US National Cancer Institute
News image
American Society for Clinical Oncology
News image
News imageNews image
The BBC is not responsible for the content of external internet sites.

News image
News image
News image
News imageIn this section
News image
Disability in depth
News image
Spotlight: Bristol inquiry
News image
Antibiotics: A fading wonder
News image
Mental health: An overview
News image
Alternative medicine: A growth industry
News image
The meningitis files
News image
Long-term care: A special report
News image
Aids up close
News image
From cradle to grave
News image
NHS reforms: A guide
News image
NHS Performance 1999
News image
From Special Report
NHS in crisis: Special report
News image
British Medical Association conference '99
News image
Royal College of Nursing conference '99
News image

News image
News image
News image